Articles On Rhythm Biosciences (ASX:RHY)

Host Tylah Tully speaks with Rhythm Biosciences (ASX:RHY) CEO & managing director Dr David Atkins about the company’s transition from R&D to revenue generation, following the launch of its flagship product, ColoSTAT. ColoSTAT is a b...

ASX lifts from lows of -1.5% to slide -0.65 Energy, utilities, materials, consumer staples make gains Banks and info tech retreat sharply   Aluminium and gold gains limit losses The S&P/ASX 200 had fallen 0.65% by trade’s end, shoved...

A slew of biotechs are raising funds on the back of positive announcements Genetic Signatures wields the scythe in cost-cutting blitz Aroa completes a key trial while Cynata is almost done, too Junior ASX biotechs are successfully raising...

ASX slips 0.1% with six of 11 sectors in the green Energy leads gains alongside defensive sectors Info tech leads losses   Market runs out of steam The S&P/ASX 200 dipped just 0.1% today, knocking 8.6 points off the top. As expected,...

First commercial sales complete in the Philippines, opening South East Asian market Sale comes just weeks after commercial partnership with Digistain, inked March 4 Further sales expected as pilots advance in several other SE Asian countri...

Pitt Street values Rhythm at more than double current trading price Series of significant milestones achieved in past 12 months Company starting to look overseas for growth   Special Report: Sydney-based Pitt Street Research sees plenty o...

ASX healthcare companies teaming up with universities to develop new therapies Entropy Neurodynamics advancing psychedelic-derived therapies through university-led clinical trials Three ASX companies are industry tenants at the University...

Rhythm activates collection centres with 4Cyte Pathology for blood-based ColoSTAT colorectal cancer test Initial network of 38 blood collection sites across major cities in Queensland, NSW and Victoria Scale-up can proceed directly with ph...

Host Tylah Tully sits down with Rhythm Biosciences (ASX:RHY) CEO and managing director Dr David Atkins after the company receives National Association of Testing Authorities accreditation for its ColoSTAT blood test.  Rhythm has also locked...

ASX tips up 0.59% for third day of gains Oil slides; lithium and gold prices steady Poor breadth with just 87 stocks and four sectors rising   ASX edges cautiously higher Australian markets marked another day of cautious progress, resisti...

Rhythm completes the first commercial sale of its blood-based ColoSTAT colorectal cancer test Sale marks start of the company’s commercial clinical diagnostic testing operations First patient’s blood samples collected and transported to Rh...

Rhythm’s long quest to develop better bowel cancer test starts to reap financial rewards Imugene goes to the well after promising blood cancer trial results Adherium says its asthma monitoring tool reduces hospitalisations Medical diagn...

S&P/ASX 200 dives, bleeding 2.85% Weakest breadth all year with just nine companies rising Energy sector climbs as all other sectors freefall   Oilmageddon arrives on Australian shores The price of oil spiked once again today, shootin...

Rhythm’s ColoSTAT blood test for colorectal cancer accredited by The National Association of Testing Authorities Accreditation confirms the test meets clinical laboratory standards for quality, competence and traceability Test now included...

Rhythm Biosciences signs distribution agreement with UK cancer diagnostics group Digistain to roll out geneType across Southeast Asia Initial launch in the Philippines, with the intention to expand into additional regional markets as the p...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

ASX drops 0.6% as Trump lifts global tariffs to 15% Gold shines, materials the only sector firmly higher Tech tumbles as AI names lead market retreat It was a jittery start to the week for local investors, with the ASX shedding 55.40 poin...

ASX closes 0.24% higher as BHP lifts on 28% jump in half yearly profit to US$5.64 million on strong copper earnings Cosmos Metals up 35% as takeover target EAU Lithium executes negotiation deal with Bolivia’s state-owned lithium company  K...

Rhythm enters non-exclusive distribution service agreement with 4Cyte Pathology for its ColoSTAT blood-based bowel cancer test The deal provides access to more than 1000 patient collection centres across NSW, Victoria, Queensland and Austr...

Botanix and Adherium have raised funds at a steep discount to their prevailing share price Rhythm Biosciences and EZZ Life Sciences have entered key distribution compacts here and abroad Tetratherix banishes post-surgical scarring   Inves...

ASX 200 closes 1.66% higher to 9,014.80, setting a new 50-day high CBA rises more than 7% after posting $5.45 billion profit for H1 FY26  Healthcare giant CSL falls 5.75% after its latest half-year results    It was a tale of two heavywei...

First physician enrolled in access program for Rhythm’s ColoSTAT blood test to detect bowel cancer Program marks ColoSTAT’s entry into structured commercial deployment and Rhythm’s first pathway to routine paid clinical use Establishes con...

ASX climbs for a second session, adding 0.19% Strong breadth, with nine sectors and 123/200 stocks rising Info tech leads gains with support from materials   Market inches higher The ASX 200 held onto its gains today, ticking up 0.19% wit...

Highlights ChartWatch ASX scans reflect contrasting sector participation across retail, technology, property, and resources. Companies across All Ordinaries, ASX 100, ASX 200, and ASX 300 feature in recent market groupings....

ASX 200 plunges 180 points to fall 2.03% Zero areas of resistance, only 6 stocks of 200 in the green Info tech absolutely smashed, returning to Dec 2023 levels   Chaos comes home to roost After weeks of uncertain trade and volatile surges...

ASX slides 38.6 points or 0.43% Weak breadth despite eight sectors green with just 87 stocks rising Materials and energy lead losses while banks rise   Volatility rules Volatility is the word of the month – and maybe the year. The market...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

ASX stages swift recovery, climbing 0.89% or 78 points 10 of 11 sectors on the up; just utilities left in the cold Info tech and materials lead gains   Market powers through RBA rate hike The market recovered its footing after four sessio...

Highlights Market sentiment steadied as global cues improved Resources and technology shares regained momentum Central bank focus shaped cautious positioning Australian shares regained balance as technology and resourc...

Host Tylah Tully looks at Rhythm Biosciences (ASX:RHY) latest news after the company secured a key manufacturing partner in the US, moving closer to the commercial rollout of its colorectal cancer blood test, ColoSTAT. Rhythm has executed a...

ASX recovers from session lows of -0.84% to dip just -0.07% Info Tech extends losses, falling to Feb 2024 levels Uranium and gold stocks fuel materials and energy gains   Tech in harsh retreat The struggling info tech sector took another...

Rhythm partners with Australian Genome Research Facility to establish Australian commercial-scale processing for geneType The partnership will process more than 100,000 tests per year to support local customer demand Partnership to support...

Rhythm Biosciences secures US platform partnership with CancerIQ to accelerate geneType commercial adoption Cancer IQ is a leading US digital oncology platform used by more than 65 health systems encompassing 345 clinics Partnership positi...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

ASX slides again, down 0.37% Eight of 11 sectors lower, with 112/200 stocks falling Materials surges on gold price once again   Materials pumps higher on fresh gold peak The materials sector has truly become the engine room of the ASX in...

First peer-reviewed publication validates the first generation ColoSTAT clinical performance with 81.3% sensitivity and 91.% specificity The performance is comparable to stool-based test used in Australia’s National Bowel Cancer Screening...

ASX gives up early gains, ticking up just 12 points or 0.14% Weak breadth despite eight sectors green with just 101 stocks rising Banks and financial stocks weigh heavy   Market gives up momentum on bank slide A spike in oil prices pushin...

Enhanced geneType colorectal cancer test now includes genetic, clinical and lifestyle risk factors New gender-specific variables deliver stronger predictive accuracy Peer-reviewed validation confirms improved performance of new model   Sp...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin MELBOURNE, Australia, Jan. 14, 2026 /PRNewswire/ – Rhythm Biosciences Ltd (‘RHY‘,...

ASX climbs 0.15% on solid breadth with 143 stocks rising 8 of 11 sectors higher, led by info tech Banks retreat despite cooling inflation read Rare Earth export restrictions spotlights ASX stocks The ASX 200 finished up 0.15% or 12.8 poin...

Just 3 of 11 sectors made gains in December Gold and silver hit new all-time highs Analysts are predicting an interest rate hike by February Santa Rally fails to fully materialise The ASX 200 had a lacklustre performance in December, addi...

ASX bounces 95.8 points, adding 1.1pc Broad gains once again with all sectors higher Real estate, banks, lead market higher   Broad strength, strong breadth The ASX 200 is already sipping the eggnog if today’s performance is anything to g...

Rhythm and US-based datma team up to apply federated real-world data to genomic diagnostic development Rhythm to evaluate how datma.FED platform may contribute to further development of its genomic-integrated cancer risk prediction tools...

ASX 200 falls 0.16% or 13.7 points 10 of 11 sectors down with 98 stocks lower and 93 rising Materials alone in the green as XGD touches new record high   Gold and lithium stocks resist the tide A familiar game of tug-of-war played out on...

Host Tylah Tully sits down with Rhythm Biosciences (ASX:RHY) CEO and managing director David Atkins after the company reached a long-awaited commercial milestone, officially bringing its flagship ColoSTAT bowel cancer screening test to mark...

ASX climbs 105.3 points, or 1.23%, on broad rally Eight of 11 sectors on the up with 138 stocks rising XGD hits new all-time high after surging 4.42%   XGD gold index rises to new heights The ASX 200 had its best showing in a month, risin...

Rhythm starts commercialisation in Australia of its flagship blood test for bowel cancer ColoSTAT The launch follows renewal of its ISO accreditation, marking its transition to its first market launch ColoSTAT will initially be offered as...